Keros Therapeutics, Inc.

KROS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$187,353-$152,992-$104,679-$58,744
Dep. & Amort.$1,229$815$674$378
Deferred Tax$0$0$0$46
Stock-Based Comp.$34,872$28,763$18,682$11,722
Change in WC-$11,437-$2,650$14,308-$16,070
Other Non-Cash$1,820$1,556$953$520
Operating Cash Flow-$160,869-$124,508-$70,062-$62,148
Investing Activities
PP&E Inv.-$1,931-$2,464-$1,241-$1,024
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$1,931-$2,464-$1,241-$1,024
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$380,134$175,825$119,578$28,171
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$11,687$3,131$731$379
Financing Cash Flow$391,821$178,956$120,309$28,550
Forex Effect$0$0$0$0
Net Chg. in Cash$229,021$51,984$49,006-$34,622
Supplemental Information
Beg. Cash$332,359$280,375$231,369$265,991
End Cash$561,380$332,359$280,375$231,369
Free Cash Flow-$162,800-$126,972-$71,303-$63,172